Impairments in antifolate transport are common in retinoblastoma tumor samples

Pediatric Blood and Cancer

Volumn 50, Issue 3, 2008, Pages 573-576

  Gorlick, Richard G ^a   Abramson, David H ^a   Sowers, Rebecca ^a   Mazza, Beth Anne ^a   Dunkel, Ira J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Developmental therapeutics; Drug resistance; Methotrexate; Retinoblastoma

Indexed keywords

DIHYDROFOLATE REDUCTASE; FOLIC ACID; MARKER; METHOTREXATE; PT 430; REDUCED FOLATE CARRIER; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CANCER RECURRENCE; CANCER RESISTANCE; CANCER RISK; CHILD; FEMALE; FOLATE METABOLISM; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; INFANT; MALE; PRIORITY JOURNAL; RETINOBLASTOMA; SECOND CANCER; TRANSPORT KINETICS;

ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FOLIC ACID ANTAGONISTS; HUMANS; INFANT; MALE; MEMBRANE TRANSPORT PROTEINS; METHOTREXATE; NEOPLASM PROTEINS; NEOPLASMS, SECOND PRIMARY; RETINAL NEOPLASMS; RETINOBLASTOMA; TETRAHYDROFOLATE DEHYDROGENASE; TRIMETREXATE; TUMOR CELLS, CULTURED;

EID: 38549084679     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21266     Document Type: Article

References (31)

1. Kingston JE, Hungerford JL, Madreperla SA, Plowman PN. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol 1996;114:1339-1343.
2. Murphree AL, Villablanca JG, Deegan WF III, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996;114:1348-1356.
3. Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 1996;114:1321-1328.
4. Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000;18:12-17.
5. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol 2002;120:1653-1658.
6. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction plus focal therapy for retinoblastoma: Factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 2002;133:657-664.
7. Gorlick R, Goker E, Trippett T, et al. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996;335:1041-1048.
8. Bertino JR. Ode to methotrexate. J Clin Oncol 1993;11:5-14.
9. Chan HS, Canton MD, Gallie BL. Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines. Anticancer Res 1989;9:469-474.
10. Trippett T, Schlemmer S, Elisseyeff Y, et al. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia. Blood 1992;80:1158-1162.
11. Guo W, Healey JH, Meyers PA, et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 1999;5:621-627.
12. Gorlick R, Goker E, Trippett T, et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 1997;89:1013-1018.
13. Matherly LH, Taub JW, Ravindranath Y, et al. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphocytic leukemia. Blood 1995;85:500-509.
14. Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: An extended follow-up. J Clin Oncol 2005;23:2272-2279.
15. Abramson DH, Frank CM. Second nonocular tumors in survivors of bilateral retinoblastoma: A possible age effect on radiation-related risk. Ophthalmology 1998;105:573-580.
16. Moll AC, Imhof SM, Schouten-Van Meeteren AYN, et al. Second primary tumors in hereditary retinoblastoma: A register-based study, 1945-1997. Is there an age effect on radiation-related risk? Ophthalmology 2001;108:1109-1114.
17. Abramson DH, Schefler AC. The treatment of retinoblastoma. In: Albert DM, Polans A, editors. Ocular Oncology. New York; Marcel Dekker: 2003. pp 353-376.
18. Abramson DH, Schefler AC. Update on retinoblastoma. Retina 2004;24:828-848.
19. Chan HS, Gallie BL, Munier FL, Beck Popovic M. Chemotherapy for retinoblastoma. Ophthalmol Clin N Am 2005;18:55-63.
20. Hawkins MM, Wilson LM, Burton HS, et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 1996;88:270-278.
21. Nishimura S, Sato T, Ueda H, Ueda K. Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma. J Clin Oncol 2001;19:4182-4183.
22. Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999;340:351-357.
23. Lacerda JF, Goker E, Kheradpour A, et al. Selective treatment of SCID mice bearing methotrexate transport resistant human acute leukemia tumors with trimetrexate and leucovorin protection. Blood 1995;85:2675-2679.
24. Garcia-Bournissen F, Moghrabi A, Krajinovic M. Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of gamma glutamyl hydrolase (GGH) gene. Leuk Res 2006; [Epub ahead of print]
25. Krajinovic M, Moghrabi A. Pharmacogenetics of methotrexate. Pharmacogenomics 2004;5:819-834.
26. Laverdiere C, Chiasson S, Costea I, et al. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002;100:3832-3834.
27. Goto Y, Yue L, Yokoi A, et al. A novel single-nucleotide polymorphism in the 3′-untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin Cancer Res 2001;7:1952-1956.
28. Haller DG. Trimetrexate: Experience with solid tumors. Semin Oncol 1997; S18-71-S18-76.
29. Balis FM, Patel R, Luks E, et al. Pediatric phase I trial and pharmacokinetic study of trimetrexate. Cancer Res 1987;47:4973-4976.
30. Pappo AS, Vats T, Williams TE, et al. Phase I trial of trimetrexate in pediatric solid tumors: A Pediatric Oncology Group study. Med Pediatr Oncol 1993;21:280-282.
31. Hum M, Holcenberg JS, Tkaczewski I, et al. High-dose trimetrexate and minimal-dose leucovorin: a case for selective protection? Clin Cancer Res 1998;4:2981-2984.